Skip to main content

Table 2 Correlations between changes in [18F]-FDG lung uptake after 3 months of antifibrotic treatment and the evolution of functional parameters

From: Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients

Correlation test (Pearson)

∆SUVmean

∆SUVmax

∆SUVmean-corr

∆TBR

∆TLG

∆MLV

Lung function tests

Evolution at one year (slope of the least squares)

FVC

r

−0.15

−0.21

−0.04

0.15

−0.20

−0.18

p

0.46

0.31

0.87

0.47

0.34

0.38

TLC

r

0.01

0.08

0.13

0.09

0.094

0.12

p

0.97

0.69

0.54

0.68

0.65

0.57

DLCO

r

−0.14

0.10

−0.11

0.18

−0.09

− 0.06

p

0.49

0.61

0.59

0.39

0.63

0.78

6-MWT

Δ SaO2 post-exercise between baseline and after one year

r

−0.15

−0.31

−0.02

0.13

− 0.20

−0.20

p

0.56

0.24

0.95

0.64

0.47

0.45

Δ traveled distance between baseline and after one year

r

−0.25

−0.05

−0.08

0.22

− 0.10

−0.08

p

0.37

0.86

0.77

0.43

0.74

0.78

  1. Correlation tests were performed between the Δ[18F]-FDG uptake after three months of treatment and the evolution of lung function tests (FVC, TLC, and DLCO) and the evolution of the six-minutes walking test (6-MWT). r: correlation coefficient, p: p value